TechMARK movers: Norgine takes ProStrakan stake

ProStrakan shares have jumped following the announcement yesterday evening that Norgine had acquired a 12.6% stake. Norgine has said that it has no current intention of making an offer for the Scotland-based speciality pharmaceuticals company. Privately-owned Norgine is more than one hundred years old and Peter Stein, a grand-nephew of the founder, is chief executive. It already has a subsidiary and manufacturing facilities in the UK, as well as businesses in Ireland, France, Portugal, Spain, Germany, Belgium, the Netherlands, Denmark, Switzerland and Austria. Revenues hit €257m in 2009. Movicol, the world's leading prescription laxative, accounts for 50% of sales. Gene therapy developer Oxford Biomedica says that the FDA has granted an Investigational New Drug (IND) application for the Phase I/II clinical development of RetinoStat.RetinoStat is one of four ocular gene therapy programmes expected to go into clinical development early next year. FTSE TechMARK - RisersProStrakan Group (PSK) 85.25p +20.49%Renovo Group (RNVO) 38.75p +3.33%Torotrak (TRK) 20.75p +2.47%Optos (OPTS) 110.00p +2.33%Filtronic (FTC) 38.00p +2.01%Dialight (DIA) 430.00p +1.78%Corin Group (CRG) 49.25p +0.51%Asterand (ATD) 11.75p 0.00%Triad Group (TRD) 18.00p 0.00%FTSE TechMARK - FallersKofax (KFX) 256.00p -4.12%Parity Group (PTY) 9.00p -2.70%Puricore (PURI) 57.50p -2.54%Antisoma (ASM) 6.75p -2.17%Axis-Shield (ASD) 260.00p -1.89%Innovation Group (TIG) 13.25p -1.85%Alterian (ALN) 188.25p -1.70%Telecity Group (TCY) 456.60p -1.55%Vectura Group (VEC) 63.50p -1.55%Oxford Biomedica (OXB) 9.50p -1.35% Oxford Biomedica